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ABSTRACT 
 The objective of this study was to validate a simple and precise Ultra 
Performance liquid chromatographic method with Tandem Mass Spectrometry-
(AB SCIEX) method for the determination of Asenapine and N-Desmethyl 
Asenapine (metabolite) in human plasma using Asenapine Maleate 13C D3 as 
Internal Standard (IS). The precision and accuracy data have to fulfill the 
requirements for quantification of the analytes in biological matrices to generate 
data for bioequivalence, bioavailability, pharmacokinetic or toxicology 
investigations. A Hypersil GOLD C18, 5µ column having 4.6 x 50 mm internal 
diameter in binary gradient mode with flow rate was 0.6 mL/min of mobile 
phase containing acetonitrile and ammonium formate (90:10) were used. The 
experiments were performed by loading in UPLC with a triple quadruple mass 
spectrometer, operating in the multiple reaction monitoring (MRM) modes. The 
method was validated over the concentration range of 0.1080 – 35.314 
ng/mL(ANALYTE) and 0.1060 – 34.47 ng/mL (METABOLITE), by using 500 
µL plasma samples.The mean recovery of Asenapine (81%) and N-Desmethyl 
Asenapine (80%) from spiked plasma samples was consistent and reproducible. 
The method was validated for linearity, accuracy, precision, specificity, and 
robustness. The intra- and inter-day precision and accuracy values were found 
to be within the assay variability limits as per the FDA guidelines. The 
developed assay method was applied to a clinical pharmacokinetic study in 
human volunteers.  
 
Keywords: Asenapine, N-Desmethyl Asenapine , Asenapine Maleate 13C D3, 
LC-MS/MS, Linearity, Validation. 
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1. INTRODUCTION 
 
Analytical sciences are useful in the Qualitative and Quantitative analysis of 
pharmaceuticals and other compounds. Analytical methods are developed 
according to Regulatory guidelines. 
1.1. Bio analysis 
Bioanalysis is a sub-discipline of analytical chemistry covering the quantitative 
measurement of  biological molecules, proteins, DNA, drugs and 
their metabolites in the biological systems. Bio analysis also applies to drugs 
used for illicit purposes, forensic investigations, anti-doping testing in sports, 
and environmental concerns. 
1.2. Modern Bio analytical Chemistry 
Many scientific endeavours are dependent upon accurate quantification of drugs 
and endogenous substances in biological samples. The focus of bio analysis in 
the pharmaceutical industry is to provide a quantitative measure of the active 
drug and/or its metabolite(s) for the purpose of 
pharmacokinetics, toxicokinetics, bioequivalence and exposure–response 
(pharmacokinetics /pharmacodynamics studies). Bio analysis was traditionally 
thought of in terms of measuring small molecule drugs. However, the past 
twenty years has seen an increase in biopharmaceuticals  
(e.g. proteins and peptides), which have been developed to address many of the 
same diseases as small molecules. Modern drugs are more potent, which has 
required more sensitive bio analytical assays to accurately and reliably 
determine these drugs at lower concentrations. This has driven improvements in 
technology and analytical methods. 
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1.3. Diseases and Drug: 
Psychosis is defined as a serious mental disorder as characterized by defective 
or lost contact with reality often with hallucinations or delusions. Bipolar mood 
disorder, in which the patient cycles from severe depression to feelings of 
extreme excitation. 
Anti-psychotic drugs control the symptoms of psychosis, and in many cases are 
effective in controlling the symptoms of Bipolar Disorder which causes unusual 
shifts in mood , energy, activity levels, ability to perform daily task and also 
Schizophrenia with the symptoms of Hallucination, delusions, disorders in 
thinking, flat effect, social withdrawal, cognitive deficits.  Atypical 
Antipsychotic drugs are helpful in controlling mental disorders with less side 
effects. Some drugs include:  
1. Chlorpromazine 
2. Risperidone 
3. Haloperidol 
4. Olanzapine 
5. Asenapine 
The efficacy of asenapine is through a combination of potent antagonist activity 
at D2 and 5:HT2A receptors with the affinity to 5:HT2A receptors 19 times 
higher than that of D2 receptors. Pre clinical test have shown a low tendency for 
EPS, whereas other drugs that target dopamine D2receptors. This is the major 
reason to develop this drug, in order to cure the mental disorders.   
Literature survey reveals that Asenapine and three metabolites were estimated 
in human plasma by LC/MS method. One is N-Desmethyl Asenapine obtained 
from the demethylation of Asenapine. 
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1.4. Bioanalytical techniques 
Some techniques commonly used in bio analytical studies include: 
1. Hyphenated techniques 
LC–MS (liquid chromatography–mass spectrometry) 
GC–MS (gas chromatography–mass spectrometry) 
LC–DAD (liquid chromatography–diode array detection) 
CE–MS (capillary electrophoresis–mass spectrometry) 
2. Chromatographic methods 
HPLC (high performance liquid chromatography) 
GC (gas chromatography) 
UPLC (ultra performance liquid chromatography) 
Supercritical fluid chromatography 
3. Electrophoresis 
4. Ligand binding assays 
Dual polarization interferometer 
ELISA (Enzyme-linked immunosorbent assay) 
MIA (magnetic immunoassay) 
RIA (radioimmunoassay) 
5. Mass spectrometry 
6. Nuclear magnetic resonance 
The most frequently used techniques are: liquid chromatography coupled with 
tandem mass spectrometry (LC–MS/MS) for 'small' molecules and enzyme-
linked immunosorbent assay (ELISA) for macromolecules 
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1.5. LC – MS  
It is an analytical instrument that combines the physical separation capabilities 
of liquid chromatography with the mass analysis capabilities of mass 
spectrometry. It is used for analyzing high sensitive compounds. 
1.5.1. Application 
1. Qualitative and quantitative analysis 
2. Impurity profiling 
3. Metabolite studies 
4. Pharmacokinetics and bio medical studies. 
 
Fig – 1: UPLC- MS/MS ( Aquity – AB SCIEX) 
1.5.2. Advantages of LC–MS/MS: 
1. Here we can select our interested ion from the chromatograph and 
accumulate as fragmentation for further MS study. 
2. Label free analysis (reduced protein loading, increased sequence 
coverage for protein and proteome coverage). 
3. Easy to fractionate the complex mixtures. 
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In this work RP-HPLC with Multiple Quadrupole tandem Mass Spectroscopy 
(API 4000) has been used to develop and validate a method for the 
determination of the drug Asenapine in human plasma  in order to achieve a 
minimum Retention time, good precision and accuracy within a lowest Range of 
Concentration.  
1.6. ASENAPINE  
Drug Name: Asenapine                                                                   
Iupacname:(3aR,12bR)-rel-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-
dibenz(2,3:6,7)oxepino[4,5-c]pyrrole (2Z)-2-butenedioate (1:1) 
Molecular Formula: C17H16ClNO·C4H4O4 (and enantiomer)  
Molecular weight: 401.84(285.8 as free base.) 
Category: Antipsychotic Agents 
Description:  SAPHRIS is a novel antipsychotic, belonging to the dibenzo-
oxepino pyrroles. It has antagonist activity on the dopamine 2 (D2) and 
serotonin (5-HT)-2A receptors.  
Solubility:  The solubility of asenapine (active entity) in water is 3.7 mg/mL, in 
0.1M HCl is 13 mg/mL and in aqueous buffers of pH 4.0 and 7.0 the solubility 
is 3.8 mg/mL and 3.0 mg/mL, respectively.  
 pKa:  is 8.6 (determined in water/methanol). Asenapine has a log P (n-
octanol/water) of 4.9 for the neutral species and 1.4 for the cationic species. 
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1.7. N- DESMETHYL ASENAPINE: 
 Molecular Formula: C16H14ClNO.HCl,  
 Molecular Weight: 271.75 
 Cmax = 0.39ng/ml 
Structure 
  
    Asenapine 13C-D3               Asenapine Maleate               N-Desmethyl Asenapine  
Fig – 2: Structure of Analyte, Metabolite and IS 
1.8. AIM & OBJECTIVE OF PRESENT WORK: 
To develop a sensitive, precise and accurate method for determination of 
Asenapine and its metabolite by Bioanalytical Method in human plasma using 
LC-MS/MS. 
The main objectives of the RP-HPLC-MS/MS  method development to rapidly 
assay and determine the related substances of Asenapine in the pharmaceutical 
formulation.   
 To develop an efficient method for analysis of Asenapine and its 
metabolite using LC-MS/MS. 
 To perform pre- method validation experiments.  
 To fully validate the developed method by studying various parameters 
like accuracy, specificity, matrix effect etc.  
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2. LITERATURE REVIEW 
 
2.1. Analytical sciences and Bio analysis: 
                   Qualitative and quantitative chromatographic analyses are used  
extensively in all areas of analytical sciences. Due to the high sensitivities of the 
detection instruments available today the techniques are invaluable in the 
analysis of environmental samples , in chemical ecology studies, for forensic 
purposes, in pharmaceutical and clinical studies, in chemical biology and in 
virtually any situation where they might find an application. (Anthony D. 
Wright et al-2012)[3] 
                 The safety and efficacy of biopharmaceuticals is controlled by 
measurements of their quality attributes. To measure these attributes for protein 
pharmaceuticals, a set of analytical methods are developed that have to meet the 
requirements specified by the International Conference on Harmonization (ICH) 
guideline. (Izydor Aposto et al, 2012)[14] 
                 LC-MS based method that utilized both RPLC and HILIC separations 
was carried out, followed by multivariate data analysis to discriminate the 
global urine profiles of BC patients and healthy controls. The purpose of this 
study was to identify a potential biomarker pattern in urine using metabonomics 
to aid non invasive BC detection using complementary chromatographic 
techniques. (Wei Hang et al., - 2011)[31] 
                Metabolomics involves the unbiased quantitative and qualitative 
analysis of the complete set of metabolites present in cells, body fluids and 
tissues, which is done by development of a method using Gas Chromatography 
– Mass Spectroscopy.( Maud M. Koek  et al., 2010).[24] 
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2.2. Diseases and Drug:  
The development of sublingual asenapine began in 1996 for the treatment 
of schizophrenia, and in 2004 for the treatment of bipolar disorder. Asenapine is 
classified as a dibenzo-oxepino pyrrole and has properties that are most similar 
to those of quetiapine, olanzapine, and clozapine. (Maurizio Pompili et al., 
2011) [25] 
As with other antipsychotic agents, asenapine exhibits a higher binding 
affinity for the 5HT2A receptor compared with D2 receptors. Moreover, 
asenapine has a broad range of effects on other neurotransmitter systems. One 
major difference between asenapine and most other atypical antipsychotics is 
that it exhibits little muscarinic receptor antagonist effects, which may produce 
a less cognitively deleterious profile, but it may result in weight gain. (Maurizio 
Pompili et al., 2011).[25] 
Asenapine is a new atypical antipsychotic agent currently under 
development for the treatment of schizophrenia and bipolar disorder. It has high 
affinity for various receptors including antagonism at 5HT2A, 5HT2B, 5HT2C, 
5HT6 and 5HT7 serotonergic receptor subtypes, α1A, α2A, α2B and α2C 
adrenergic and D3 and D4 dopaminergic receptors.( David Taylor et al., - 
2009)[7]. 
Asenapine was initially approved by the US Food and Drug 
Administration (FDA) in 2009 for the treatment of acute schizophrenia and 
acute manic or mixed episodes associated with bipolar I disorder in adults, and 
subsequently received approval for the maintenance phase of schizophrenia and 
for adjunctive use with lithium or valproate for acute manic or mixed episodes 
associated with bipolar I disorder. (Leslie Citrome – 2011)[21]. 
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Amisulpride is a highly selective benzamide with 10 × higher affinities to 
D2 and D3 receptors than sulpiride and with little activity at serotonergic, 
histaminergic, or muscarinic receptors. While the agonistic effects on 
presynaptic D2/D3 receptors prevail at lower doses (increased dopamine 
transmission), at higher doses, amisulpride acts preferentially on postsynaptic 
D2/D3 receptors, reducing dopaminergic transmission. Asenapine will be 
evaluated for whether it: a) causes a reduction in symptoms of schizophrenia.    
(Daniel Huys et al.,- 2012)[6]. 
2.3. Chemistry: 
                 Asenapine (trans-5-chloro-2-methyl-2, 3, 3a, 12b-tetrahydro-
1H dibenz [2,3:6,7] oxepino[4,5- c]pyrrolidine) maleate (Org 5222) was 
developed by altering the structure of mianserin. The molecular formula of 
asenapine maleate is C17H16CINO.C4H4O4 with a molecular weight of 
401.84. Asenapine is quite stable in crystalline form although excessive light 
can induce degradation. Clinical studies have used fast-dissolving highly porous 
asenapine tablets. (Arpi MinassianJared W Young – 2012)[4]. 
                Asenapine maleate is chemically (3aRS,12bRS)—chloro-2-
methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole(2Z)-2 
butenediate is a atypical antipsychotic drug. (Aneesh T.P. et al., 2012)[1]. 
              The solubility of asenapine (active entity) in water is 3.7 mg/mL, 
in 0.1M HCl is 13 mg/mL and in aqueous buffers of pH 4.0 and 7.0 the 
solubility is 3.8 mg/mL and 3.0 mg/mL, respectively.  pKa is 8.6 (determined in 
water/methanol). Asenapine has a log P (n-octanol/water) of 4.9 for the neutral 
species and 1.4 for the cationic species. (EMEA/H/C/001177)[10]. 
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  Major metabolic routes were direct Glucuronidation and N 
Desmethylation.  The principal circulating metabolites were Asenapine 
N+glucuronide,N-desmethylasenapine-N-carbamoyl-glucuronide,N-
desmethylasenapine and Asenapine 11-O-sulfate.(Jacobs et al., 2010) [15]. 
 N-desmethyl Asenapine is not intended for the for the diagnostic and 
therapeutic uses. (EMEA) [10]. 
 The peak plasma concentration of Asenapine and its metabolite N- 
Desmethyl Asenapine in plasma for 5mg/10mg dose are 4ng/ml and 0.39ng/ml 
at tmax approximately 1 hr. (EMEA/H/C/001177) [10]. 
2.4. Mechanism of action of Asenapine: 
Consistent with other atypical antipsychotics asenapine exhibits a higher 
binding affinity for the 5HT2A receptor compared to D2 receptors. Moreover, 
asenapine exhibits a broad range of effects on other neurotransmitter systems 
including 5-HT2C, 5-HT7, 5-HT2B, 5-HT6, α2B, D3, H1, D4, α1A, α2A, α2C, 
D2L, D1, D2S, 5-HT1A, 5-HT1B, and H2 receptors.(Arpi MinassianJared W 
Young – 2012) [4]. 
It is an antagonist at 5-HT , dopamine and α-adrenergic receptors and has 
high affinity for dopamine( D2) and serotonin( 5-HT2A) receptors and its 
efficacy is mainly mediated through the combination of antagonist activity at 
D2 and 5-HT2A receptors. It is indicated for treatment of various psychotic 
conditions like schizophrenia and bipolar disorders in adults4,5,6 and mainly 
works by controlling the psychotic symptoms through antagonism of selected 
dopamine and serotonin receptors in the CNS. (Aneesh T.P. et al., 2012) [1]. 
The mechanism of action of asenapine, as with other drugs having 
efficacy in schizophrenia and bipolar disorder, is not fully understood.  
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However, based on its receptor pharmacology, it is proposed that the efficacy of 
asenapine is mediated through a combination of antagonist activity at D2 and 5-
HT2A receptors. Actions at other receptors e.g., 5-HT1A, 5-HT1B, 5 HT2C, 5-
HT6, 5-HT7, D3, and α2-adrenergic receptors, may also contribute to the 
clinical effects of asenapine. (Jacobs et al., 2010) [15]. 
2.5. Pharmacokinetics:  
Absorption of asenapine is rapid with peak plasma concentrations 
occurring within 0.5 to 1.5 hours. The average peak plasma concentrations at 
steady state of 5 and 10 mg twice daily were 3.6ng/mL and 7.0ng/mL 
respectively. The absolute bioavailability of sublingual asenapine at 5 mg is 
35%. Increasing the dose from 5 to 10 mg twice daily (a two-fold increase) 
results in less than linear (1.7 times) increases in both the extent of exposure 
and maximum concentration. The absolute bioavailability of asenapine when 
swallowed is low (< 2% with an oral tablet formulation). 
Asenapine is rapidly distributed and has a large volume of distribution 
(approximately 1700L), indicating extensive extravascular distribution. 
Asenapine is highly bound (95-97% at 1-500ng/mL) to plasma proteins in vitro, 
including albumin and α1-acid glycoprotein. 
Asenapine is extensively metabolised. Oxidative metabolism by 
cytochrome P450 isoenzymes (predominantly CYP 1A2) and direct 
glucuronidation by UGT1A4 are the primary metabolic pathways for asenapine. 
In an in vivo study in humans with radio-labelled asenapine, the predominant 
drug-related entity in plasma was asenapine N+-glucuronide; others included N-
desmethylasenapine, N-desmethylasenapine N-carbamoyl glucuronide, and 
unchanged asenapine in smaller amounts. 
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Asenapine is a high clearance drug, with a clearance after intravenous 
administration of 52 L/h. In a mass balance study, the majority of the 
radioactive dose was recovered in urine (about 50%) and faeces (about 40%), 
with only a small amount excreted in faeces (5-16%) as unchanged drug. 
Following an initial more rapid distribution phase, the terminal half-life of 
asenapine is approximately 24 hours. (EMEA) [10]. 
Sublingual administration of asenapine results in a rapid absorption with 
peak plasma concentrations within 0.5–1.5 hours and moderate (35%) 
bioavailability. This is in the lower to mid range of other antipsychotics which 
exhibit 20–70% bioavailability at appropriate doses. (Arpi MinassianJared W 
Young – 2012) [4]. 
2.6. METHOD DEVELOPMENT 
It is a step wise procedure or formulating the materials, conditions, and protocol 
for measuring an analyte. Laboratories may make minor modifications to 
methods to improve performance, in which case, the modified methods should 
be subject to more rigorous testing and evaluation by the laboratory.  
2.6.1. Instrumentation: 
The LC-MS system consisting of Shimadzu HPLC System consisting of 
RP- C18 column, variable wavelength programmable UV Visible Detector 
SPD-20A and rheodyne injector with 20µl fixed loop. (Aneesh T.P., et al. 
IJPPS, 2012) [1]. 
Shimadzu HPLC System with 10- at detector and rheodyne injector with 
20µl fixed loop was used. (Kiran Aarelly et al. JCPR, 2012) [23]. 
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HPLC system (1200 series model, Agilent Technologies, Waldbronn, 
Germany), Mass spectrometry API 4000 triple quadrupole instrument (ABI-
SCIEX, Toronto, Canada) using MRM. (Chhalotiya et al., -2011) [30]. 
2.6.2. Chromatographic conditions of the Instrument: 
The mobile phase consisting of methanol, n-butanol, and glacial acetic 
acid were degassed and filtered using a 0.45µm membrane filter. The eluent 
were monitored at 270 nm, flow rate was 1.0 mL/min, with ambient 
temperature, and runtime was 6 min. The volume of injection loop was 20µl. 
(Aneesh.t.p. et al. 2012) [1]. 
Hypersil ODS C18 Column - 250 X 4.6 mm (particle size of 5µ) and 
constant flow pump. Rheodyne injector with 20 µl loop. The mobile phase 
methanol was delivered at flow rate 1.0 ml/min. The mobile phase was filtered 
through a 0.45 µ membrane filter and sonicated for 15min. Analysis was 
performed at ambient temperature. (Kiran Aarelly et al., 2012) [23]. 
Various mixtures containing aqueous buffer, methanol and acetonitrile 
were tried as mobile phases in the initial stage of method development, but 
satisfactory resolution of drug and degradation peaks were not achieved. The 
mobile phase 0.02M potassium dihydrogen phosphate: acetonitrile (95:05, v/v, 
pH 3.5 adjusted with O - phosphoric acid) was found to be satisfactory and gave 
symmetric peak for ASP. (Chhalotiya et al., -2011) [30]. 
Zorbax Bonus-RP C18, 4.6 x 75 mm, 3.5µm was selected as the 
analytical column at a temperature of 30°C. The mobile phase composition was 
0.2% formic acid: methanol (35:65 v/v) at a flow rate of 0.5 mL/min. 
Amisulpride-d5 was found to be an appropriate internal standard in terms of  
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chromatography and extractability. The retention time of Amisulpride, 
Amisulpride-d5 was found to be approximately 1.1 ± 0.2 min. (Mogili et al., -
2011) [28]. 
2.6.3. Tuning:  
Turbo ion spray (API) positive mode with Unit Resolution, MRM was 
used for the detection of Amisulpride and Amisulpride-d5. The [MH] + was 
monitored at m/z: 370.1, for Amisulpride and m/z: 375.2 for Amisulpride-d5. 
Fragments of m/z: 242.0 for Amisulpride and m/z: 242.1 Amisulpride-d5 
formed from the respective precursor ions. Mass parameters were optimized as 
source temperature 500 °C, nebulizer source gas 30 (nitrogen) psi, heater gas 45 
(nitrogen) psi, curtain gas 20 (nitrogen) psi, CAD gas 7 (nitrogen) psi, Ion Spray 
(IS) voltage 5500 volts, source flow rate 500µL/min without split, entrance 
potential 10 V, collision cell exit potential (CXP) 12 V, declustering potential 
(DP) 70 V, Collision energy 38 V for Amisulpride and Amisulpride-d5. (Mogili 
et al., SP-2011) [28]. 
2.6.4. Extraction Procedure Optimization: 
To optimize sample preparation methods, SPE and LLE with different 
conditions were tested. Combination of protein precipitation and SPE was also 
used for preparation of plasma sample ASP, but it is expensive and labor 
intensive. LLE is a superior method for sample preparation. It gives cleaner 
samples compared with protein precipitation and, in some cases, better samples 
than SPE. (Liusheng Huang et al., 2012) [22]. 
The SPE extraction mirrors that used previously in the laboratory, and 
demonstrated increased process efficiency as compared to protein precipitation 
methods during assay development.(Rower et al.,.- 2012) [28] 
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Liquid-liquid extraction was used to isolate Amisulpride and 
Amisulpride-d5 from human plasma and it gave good results without 
interference. (Mogili et al., 2011) [28]. 
A 0.5 ml of plasma was mixed with 0.1 ml of internal standard solution 
and 1 ml of borate buffer of pH 9.0. The solution was vortexed and extracted 
with ethyl acetate. The upper organic layer was separated, evaporated and 
reconstituted with mobile phase.LLE method was found to be more precise than 
SPE. (Muralidharan et al., - 2011) [26] 
2.7. METHOD VALIDATION: 
Method validation. The process of testing a measurement procedure to 
assess its performance and to validate that performance is acceptable. It helps in 
finding maximum acceptable error by analysing the acceptability of the 
experiment to defined requirements. 
Once the HPLC method development was over, the method was validated 
in terms of parameters like, precision, accuracy, linearity and range, LOD, 
LOQ, recovery studies, system suitability parameters etc. For all the parameters 
percentage relative standard deviation values were calculated. The proposed 
HPLC method was validated as per ICH guidelines.  
Aneesh et al[1] describes about the various parameters of Validation. 
Linearity was obeyed in the concentration range of 10-100µg/ml and the 
correlation 0.998. The regression equation of Asenapine maleate concentration 
over its peak area ratio was found to be Y=7727x-6525, where Y is the peak 
area ratio and X is the concentration of Asenapine maleate (µg/ml). The 
intraday and interday precision studies were carried out and the percent relative 
standard deviation (% RSD) was calculated and it was found to be 0.53 and 0.98  
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respectively, which is within the acceptable criteria of not more than 2.0. The 
System suitability parameters like number of theoretical plates (N) was found 
to be 3601, tailing factor 1.1 and asymmetry factor 0.95, which indicates 
efficient performance of column. The drug solution was subjected to small, 
deliberate changes like flow rate, wavelength and pH. The results obtained were 
not affected by varying the conditions and were in accordance with the results 
in original conditions. This shows the method was robust.  
The limit of detection and limit of quantification was found to be 
5.46µg/ml and 16.57µg/ml respectively, indicates the sensitivity of the method. 
Satisfactory recovery in the range of 98.9-100% is obtained by the proposed 
method. A good percentage of recovery indicates that the proposed method is 
accurate. Estimation of Asenapine maleate in pharmaceutical dosage form was 
carried out and got 98.7% as assay value.  (IJPPS, 2012) 
Kiran Aarelly et al[23], found that, from the optical characteristics of the 
proposed method it was found that the drug obeys linearity range within the 
concentration of 2-10µg/ml. From the results shown precision it was found that 
the percent RSD is less than 2%, which indicates that the method has good 
reproducibility. From the results shown in accuracy it was found that the 
percent recovery values of pure drug from the pre analyzed solutions of 
formulations were in between 98.07- 101.28%, which indicates that the method 
is accurate.  
The system suitability parameters are within the specified limits and 
which refers the commonly used excipients and additives present in the 
pharmaceutical formulations did not interfere in the proposed method. The 
proposed method was found to be simple, precise, accurate and rapid for  
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determination of Asenapine from pure form. The mobile phase is simple to 
prepare and economical. (JCPR, 2012) 
Accuracy of the proposed method was determined by the recovery 
studies, and good %recovery (98- 101.2%) of the drug obtained indicate that the 
method is accurate. The method was found to be precise as %RSD values for 
interday and intraday was found to be less than 2. The method was also found to 
be rugged and robust as the % RSD values were found to be less than 2. The 
limit of detection and limit of quantification of the proposed method was found 
to be 1.40and 4.26 µg/ml indicating that the method developed is sensitive. The 
results of assay obtained were found to be in good agreement with the labeled 
claim, indicating the absence of interference of the excipients. (Liusheng 
Huang, Der Pharma Chemica, 2012) [22] 
Stability (Freeze - thaw, Auto sampler, Bench top, Long term). The 
concentrations ranged from 93.16 to 103.3% for amisulpride of the theoretical 
values. These results confirmed the stability of Amisulpride in human plasma 
for at least 55 days at −30°C (Mogili et al) [28]. 
Short Term Stock Solution Stability Short term stock solution stability at 
room temperature for acyclovir and internal standard the % change was -2.56 
and -6.18 respectively. Short term stock solution stability at refrigerator (2-8 
0C) : For acyclovir and internal standard the % change was -1.16 and -0.84 
respectively. Short Term Working Solution Stability Short term working 
solution stability at room temperature: One for internal standard the % change 
found is -4.62. Short term working solution stability at refrigerator (2-8 0C) for 
internal standard the % change found was 0.75. Long Term Tock and Working 
Solution Stability The long-term stock and working solution stability 
experiment were completed after completion of the study sample analysis. Long  
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term stock solution stability in refrigerator between 2-8 0C :For acyclovir and 
internal standard, the % change was 2.23 and 1.62 respectively. Long term 
working solution stability in refrigerator between 2-8 0C For acyclovir and 
internal standard, the % change found is 2.30 and -0.14 respectively. 
  Bench Top Stability The bench top stability samples each of low and 
high QC (stability samples) was kept on bench at room temperature was found 
stable at approximately 14 Hrs and 30 Min. The % change for LQC and HQC 
were 2.27 and 5.97 respectively.  
Freeze and Thaw stability (at -20 ± 5 0C) The freeze and thaw stability 
samples each of LQC and HQC were found to be stable in human plasma after 
four freeze and thaw cycles (at -20 ± 5 0C). The % change for LQC and HQC 
were 1.85 and 1.05 respectively.  
Auto sampler Stability The stability samples each of LQC and HQC 
was found to be stable for approximately 70 Hrs and 00 Min in auto sampler (at 
5 ± 3 0C). The % change for LQC and HQC were -0.78 and 0.29 respectively. 
Long term stability of Acyclovir and Internal Standard in Biological Matrix 
(Human Plasma) (P. Susantakumar et al) [29] 
Separation, Specificity/Selectivity and Sensitivity Selected blank 
human plasma from six different sources and were carried through the 
extraction procedure and chromatographed to determine the extent to which 
endogenous human plasma components may contribute to chromatographic 
interference with the  acyclovir or IS. (P. Susantakumar et al) [29] 
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The Specificity and selectivity analysis of Amisulpride and Amisulpride-
d5 using MRM function was highly selective with no interfering compounds. 
Calibration was found to be linear over the concentration range of 2.0–
2500.0ng/mL for Amisulpride (Fig. 4). The CV% for Amisulpride was less than 
3.9%. The accuracy ranged from 96.5 to 101.5% for Amisulpride. The 
determination coefficient (r2) for Amisulpride was greater than 0.9998 for all 
curves. (Chhalotiya et al., -2011) [30] 
Matrix Factor Samples of the relevant biological matrix from six 
different sources were collected. The lower calibration standard samples from 
each source were prepared and injected along with the six replicates of aqueous 
lower calibration standard level concentrations. The %CV of matrix factor for 
acyclovir and internal standard were 4.69 and 1.39 and % CV of matrix factor 
for internal standard normalized was 4.89, respectively (P. Susantakumar et 
al) [29] 
Matrix Effect The CV % of ion suppression/enhancement in the signal 
was found to be 1.2% at MQC level for Amisulpride, indicating that the matrix 
effect on the ionization of the analyte is within the acceptable range under these 
conditions. (Chhalotiya et al., -2011) [30] 
Ruggedness Different analyst with different column defines ruggedness. 
The run consisted of a calibration curve and a total of 18 spiked samples, 
including 6 replicate each of the low, medium and high quality control samples. 
The % coefficient of variation ranged from 1.03 to 12.12 and the percentage of 
nominal values ranged from 96.24 to 107.27. (P. Susantakumar et al) [29] 
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3. MATERIALS & METHODOLOGY 
3.1. CHEMICALS AND REAGENTS USED: 
Table-1:  List of chemicals and reagents used 
S.No Name Of The 
Chemical/Reagents 
Manufactures Grade 
01. Asenapine Maleate (IS) 
Clearsynth Inspiring 
Chemistry Pvt Ltd 
NA 
02. 
N- Desmethyl Asenapine 
Maleate 
Clearsynth Inspiring 
Chemistry Pvt Ltd 
NA 
03. Asenapine 13C D3 Maleate 
Clearsynth Inspiring 
Chemistry Pvt Ltd 
NA 
04. Methanol Finar HPLC 
05. Acetonitrile Fisher Scientific HPLC 
06. Ammonium Formate Loba chemie  
07. 
Potassium Di hydrogen ortho 
phosphate 
Rankem  
08. Ethyl Acetate Fisher Scientific  
09. Tertiary Butyl Methyl Ester Merck  
10. Formic acid Rankem GR 
11. Milli-Q-water Inhouse HPLC 
12. K2EDTA human plasma  Inhouse (Volunteers) NA 
13. RIA vial Abdos NA 
14. Injector vials Agilent NA 
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3.2. INSTRUMENTS USED:    
Table-2: List of instruments used 
S no 
List of instruments 
used 
Instrument 
manufacturer 
Range 
01. Micro pipette Eppendorf 2-20µL, 20-200µL, 
100-1000µL. 
02. Multipipette Handy step 20µL-25000µL 
03. Electronic balance Satrorius 0.001gm-220gm 
04. Vortex mixer Cyclo mixcer 0-2500 rpm Touch and 
continuous 
05. Vibramax 
 
Heidolph rpm=0-3000rpm 
Time=0-30min 
06. Sonicator Power sonic 420 40 kHz 
07. Refrigerated 
centrifuge 
Kendro rpm=0-5500rpm 
Time=0-30min 
08. Evaporator Zymark turbovap Pressure=0-30psi 
No. of sample=50 
09. LC-MS/MS API 4000 ANALYST – 2.5.6 
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3.3. METHOD DEVELOPMENT 
It refers to the process of formulating the materials, conditions, and protocol for 
measuring an analyte. It is the process of developing a method to determine the 
bioavailability and bioequivalence of administered drug in plasma. Method 
development is a trial and error process. It consists of various steps.  
• Preparation of stock & tuning solutions (refer appendix II) 
• Tuning of LC-MS/MS 
• Chromatographic condition optimization  
• Serial dilution 
• Aqueous linearity 
• Extraction procedure optimization 
3.3.1. TUNING  
Tuning is the adjustment of working parameters of LC-MS/MS to enable an 
operator to get the best signal possible for the analyte by optimizing the Q1 
mass, Q3 mass of analyte, metabolite and Internal Standard based on molecular 
weights. The molecular weight of Asenapine and N- Desmethyl Asenapine are 
285.8 and 271.75. Manual, semiautomatic, and automatic tuning procedures 
require the introduction of a tuning solution of the analyte of interest into the 
MS at a steady rate. It can be done either by directly injecting through syringe 
pump or by injecting the sample into the effluent of the LC by using a loop 
injection valve or tee union. 
3.3.1.1. Procedure: 
Stock solution of Asenapine was prepared as in Appendix-II and it was diluted 
to 100ng/ml to be used as Tuning Solution. Tuning solution was infused in full 
scan mode. From result, m/z of parent ion was selected. (Molecular weight).  
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Fragmentation of parent ion was determined by infusing the stock dilution in 
product ion mode and checked for m/z of various daughter ions obtained. 
Prominent and suitable daughter ion was selected by altering various parameters 
in Multiple Reaction Monitoring (MRM)  
3.3.1.2. OPTIMIZED CONDITIONS: 
Table - 3:  Optimized Tuning Parameters 
 
TUNING 
Q1 
MASS 
Q3 
MAS
S 
DWELL 
(msec) 
PARAMETERS 
DP CE CXP 
Analyte (ASEN) 286.20 229.20 200 85 30 18 
Metabolite (DES 
ASEN) 
272.10 229.20 200 70 25 18 
IS(ASEN 13CD3) 290.10 229.20 200 85 30 20 
 
 
CAD GAS : 10.00   
CUR GAS : 14.00 
GS1  : 50.00 
GS2  : 55.00 
TEM  : 400.00 
IS  : 5500.00 
EP  : 10.00 
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Fig- 3   :   Q1 scan of Asenapine 
 
Fig- 4   :   Q3 scan of Asenapine 
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Fig-5: Q1 scan of N- Desmethyl Asenapine 
 
Fig-6: Q3 scan of N- Desmethyl Asenapine 
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Fig-7: Q1 scan of Asenapine 13C D3 
 
Fig-8: Q3 scan of Asenapine 13C D3 
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The response graph depicts the response in the Y-axis and mass of the ions in 
the X-axis. The determined parent ion mass (Q1 mass) is equal to the molecular 
weight of the species plus one. This is because during the electrospray 
ionization, the ions are protonated, resulting in an increase in the charge and 
consequently, the sensitivity. Hence the mass increases by one. The cleaved 
ions (or daughter ions) are screened and the mass of the daughter ion species 
giving the highest response is chosen (Q3 mass). 
In the fig (3- 8), the response obtained for ions of various masses is shown. The 
ion with the mass which gives highest response was selected in each case for the 
parent and daughter ion scan of Asenapine, N- Desmethyl Asenapine, 
Asenapine 13C D3.  
3.3.2. CHROMATOGRAPHIC CONDITION OPTIMIZATION: 
The suitable column, mobile phase and flow rate etc had to be selected and 
optimized to develop an efficient method. 
3.3.2.1. Column and Mobile Phase 
Table - 4: Trails for column and mobile Phase 
Trail Column Mobile Phase Response 
1 XTERRA- C8 Acetonitrile: 5mM Ammonium 
Acetate (80:20)  
  Poor peak shape, 
More tailing, 
Poor Baseline Stability 
Very less response 
2 XTERRA- C8 Acetonitrile: 10mM Ammonium 
Acetate (90:10) 
Poor peak shape 
Less tailing 
Relatively better response 
3 HYPERSIL 
GOLD – C18 
Acetonitrile: 5mM Ammonium 
Acetate (80:20) 
Good peak shape, 
Very less tailing, 
Better response 
4 HYPERSIL 
GOLD – C18 
Acetonitrile: 10mM Ammonium 
Acetate (90:10) 
Good peak shape, 
least tailing, 
good baseline Stability, 
Good response. 
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Retention Time, Run time of the drug were determined. 
3.3.2.2. Flow rate and Temperature: 
  Less Flow rate improves the elution efficiency. So usually Flow rate 
must be between 0.5 and 1.0 mL/min.  
 Various temperatures for column oven and auto sampler were set to 
obtain a proper good chromatograph shape and height. 
3.3.2.3. OPTIMIZED CONDITIONS: 
Trail 4: Hypersil Gold - C18, (5µm.4.6x50mm) with Acetonitrile: 10mM 
Ammonium Acetate (90:10) as mobile phase 
 
Fig – 9: Analyte, Metabolite and IS chromatograms showing maximum 
response for optimized column and mobile phase 
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Table - 5: Optimized Chromatographic Conditions 
 
PARAMETERS 
 
OPTIMIZED CONDITIONS 
Column Hypersil Gold (50mmx4.6mm, 5µm) 
Mobile Phase Acetonitrile : 10mM Ammonium 
Acetate (90:10,v/v) 
Injection Volume 10µL 
Flow Rate 0.600 mL/min 
Column oven Temperature 40°C 
Auto sampler Temperature 10°C 
Total Run Time 3.5 mins 
Retention Time 
 
Analyte : 2.20±0.3 min 
Metabolite  : 2.10±0.3 min 
IS   : 2.20±0.3 min 
 
3.3.3. AQUEOUS LINEARITY 
3.3.3.1. Serial Dilution for CC and Aqueous QC:  
 Standards A to H have to be prepared based on the Cmax value: 
 [H]   =  Cmax x 2- Highest concn ;  
[A]   =  Cmax/64- lowest concn  
    ULOQ  =  [H]                        
    LLOQ  ~  [A] and LOQQC  
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CC 
LLOQ    =  atleast 100- 105% of Cmax       
1st STD after LLOQ  =  2xLLOQ     
STD before ULOQ  =  70-85% ULOQ 
ULOQ    =  atleast 2x Cmax  
QC      
LOQQC   =  LLOQ/STD A(100 and 105%) 
INTQC   =  5-30% of [H] 
MQC    =  30-45% of [H] 
HQC    =  70-85% of [H] 
Aqueous samples were prepared from the serial dilution on recovery basis.2% 
drug content was fixed for all standards and the amount of each dilution to be 
added was determined so as to obtain this content. Diluent used was 90:10 
methanol: water. Aqueous samples were prepared from each of the serial 
dilutions to obtain calibration curve standards (A-H) and quality control 
standards (LOQQC-HQC). 
3.3.4. EXTRACTION PROCEDURE OPTIMIZATION: 
The drug has to be extracted from the biological matrix (plasma) before 
injecting into the LC-MS/MS. Extraction procedure refers to the method used to 
separate the drug from the plasma to obtain at least a 50% recovery. To 
optimize the extraction procedure, the drug solution is spiked in matrix and 
extracted with the extraction procedure. The method giving the maximum  
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recovery of drug from the biological matrix is chosen. This is called extraction 
procedure optimization. 
 Three methods of extraction procedures in the order of increasing cost for 
performing is as follows:  
 Protein precipitation,  
 Liquid-Liquid Extraction  
 Solid Phase Extraction. 
3.3.4.1. Extraction-1 by Precipitation: 
The spiked plasma samples from the deep freezer were allowed to thaw at room 
temperature. 0.5ml was aliquoted into a clean RIA vial and 50 µl of Internal 
Standard (10µg/ml) was added. Vortexed and mixed well. 1.5ml of Acetonitrile 
was added and vibramaxed for 10 minutes. The sample was centrifuged at 
4500rpm for 10 minutes at 4ºC. 1ml supernatant was collected and evaporated 
till dryness. The residue was reconstituted with 0.5ml of mobile phase and 
injected 10 µl into LC-MS/MS. 
3.3.4.2. Extraction- 2 by Liquid-Liquid Extraction: 
Trail 1 - Ethyl Acetate: n- Hexane as Extraction Solvent: 
Spiked plasma Samples were vortexed. 500µL plasma, 50 µL IS and 300µL of 
Buffer -2(A were added in RIA vials  and vortexed. 2.5mL of Ethyl Acetate 
was added as extraction solvent and vibramaxed at 2000 rpm for 10minutes. 
This was then centrifuged at 4000rpm for 5minutes. 2mL of supernatant was 
transferred into new vials and dried in nitrogen evaporator at 40° C and 15psi. 
After drying it was reconstituted with 250µL of mobile phase Vortexed and 
loaded into LC-MS/MS by transferring into injector vials. 
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Fig - 10: LV Evaporator for drying samples 
Trial 2 – Tertiary Butyl Methyl Ether : n-Hexane as extraction solvent: 
Spiked plasma Samples were vortexed.500µL plasma, 50 µL IS and 300µL of 
Buffer -2 were added in RIA vials and vortexed. 2.5mL of TBME was added as 
extraction solvent and vibramaxed at 2000 rpm for 10minutes. This was then 
centrifuged at 4000rpm for 5minutes. 2mL of supernatant was transferred into 
new vials and dried in nitrogen evaporator at 40° C and 15psi. After drying it 
was reconstituted with 250µL of mobile phase Vortexed and loaded into LC-
MS/MS by transferring into injector vials. 
3.3.4.3. Extraction- 3 by Solid Phase Extraction: 
Spiked plasma Samples were vortexed.500µL plasma, 50 µL IS were added in 
RIA vials and vortexed. Strata X- C cartridge (60mg/3cc) was conditioned 
using 2ml methanol and 2ml water. Sample was loaded and passed through the 
cartridge. It was then washed with 2ml water and 2ml 10% methanol. 
 
 
33 
 
  
 
 
Fig-11:  48 position positive pressure equipment for Solid Phase Extraction. 
Based on the pKa value of asenapine, Elution was done with acid and base. The 
pKa value of Asenapine is 8.6, so it was eluted with Acetic acid in new 
vials.The eluted sample was loaded on to injector vials and injected into the LC-
MS/MS to obtain the chromatogram.  
 
 
 
 
 
 
 
 
34 
 
 
Table – 6:  Extraction Trails with Different mobile phase and column 
TR
AIL 
 
EXTRACTING METHOD 
RESPONSE (Area)  
CONCLUSION IS  ASEN DES ASE 
 
1 
 
Precipitation 
 
Acetonitrile 
 
23765 
 
765 
 
924 
Poor Peak Shape, recovery is 
very less. Matrix Effect is more 
 
 
 
 
2 
 
 
 
 
Liquid-Liquid 
Extraction 
 
 
 
Ethyl Acetate : n-
Hexane 
 
 
57940 
 
 
1722 
 
 
2233 
 
peak shape and peak response or 
recovery of IS was satisfactory. 
Metabolite and analyte recovery 
was relatively less 
 
Tertiary Butyl Methyl 
Ether: n-Hexane 
 
 
64456 
 
2212 
 
2058 
 
peak shape and peak response or 
recovery of IS, analyte and 
metabolite  were good and 
satisfactory 
 
3 
 
Solid Phase 
 Extraction 
 
Strata X-C Cartridge 
 
59783 
 
1993 
 
2117 
Peak area response of was  less 
than LLE and greater than  
precipitation method  
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3.3.4.4. OPTIMIZED CONDITIONS: 
Trial 2 – Tertiary Butyl Methyl Ether: n-Hexane as extraction solvent: 
 Spiked plasma Samples were vortexed. 
 500µL plasma, 50 µL IS and 300µL of Buffer -2 were added in RIA vials  
and vortexed.  
 2.5mL of TBME was added as extraction solvent and vibramaxed at 
2000 rpm for 10minutes.  
 This was then centrifuged at 4000rpm for 5minutes.  
 2mL of supernatant was transferred into new vials and dried in nitrogen 
evaporator at 40° C and 15psi.  
 After dried it was reconstituted with 250µL of mobile phase Vortexed 
and loaded into LC-MS/MS by transferring into injector vials. 
 
 
 
Fig - 12: Optimized Extraction Conditions - LLE 
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3.4. PRE-METHOD VALIDATION: 
After developing a method for the drug, the following pre- method 
validation tests were carried out : 
 Aqueous Linearity test 
 Specificity/Selectivity 
 MD Precision & Accuracy batch 
 Recovery 
 Auto sampler Carryover Test (ASCOT) 
3.4.1. AQUEOUS LINEARITY TEST: 
This is used to determine the linearity of different concentrations of aqueous 
samples. 
Procedure:  Different serial dilution was repeated and fresh aqueous standards 
(for CCs) were prepared. An appropriate regression model with minimal or no 
weighing (1/x or 1/x2) was used. Weighing factor is 1/x =1/ (concentration) and 
1/x2=1/(conc)2 . The regression model / weighing factor were selected based on 
the least deviation of the linearity curve. The standards were run in the LC-
MS/MS and linearity was evaluated. 
Acceptance Criteria: 
1. The standard curve should consist of a minimum of six standard points 
excluding blanks.  
2. The standard curve should cover the entire range of expected 
concentrations. 
3. LLOQ and ULOQ values should not be excluded. 
4. Two consecutive standards should not be excluded from the calibration 
curve. 
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5. All the CCs except the lowest should be ±15 % of the nominal value. The 
lowest values may be ±20% of nominal value. 
6. The correlation coefficient r2   should be ≥ 0.98 
7. At least 75% of non- zero standards should meet the acceptance criteria. 
3.4.2. SELECTIVITY/SPECIFICITY: 
This is to check the presence or absence of interference in the analyte or 
metabolite or IS peak because of other molecules in the plasma and to ensure 
that the method is selective towards the particular analyte. 
Procedure: Two sets of six normal lots of plasma, and one haemolysed were 
taken. One set of blank normal and blank haemolysed lots with buffer were 
processed. The aqueous LLOQ dilution were prepared and were spiked in 
another set of six normal lots of plasma and one haemolysed lot to achieve 
LLOQ concentration for analyte. After extraction both were reconstituted with 
mobile phase. Both the sets of samples were injected into the LC-MS/MS and 
the peak areas of the blank samples and respective LLOQ samples were 
compared to check the interference due to the plasma. Selectivity samples were 
prepared in the presence of both analyte and internal standard using six normal 
blank plasma and one haemolysed. 
Acceptance criteria: 
1. Peak area obtained in blank samples at retention time of the drug should 
be ≤ 20% of that obtained in LLOQ samples. 
2. Peak area obtained in blank samples at retention time of the IS should be 
≤5% of that obtained in LLOQ samples. 
3. %CV of the area ratio in the extracted LLOQ samples should be ≤ 20. 
4. S/N ratio of each LLOQ sample should be ≥5. 
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3.4.3. MATRIX EFFECT: 
This is to determine whether the biological matrix has any effect on the analyte 
that will interfere with the response peak. 
Procedure: An aqueous standard of lower and higher concentration was taken 
and injected 6times at the same vial position. Two sets of six blank normal lots 
of plasma, and one blank haemolysed were taken. To Both the sets, buffer was 
added and processed through optimized extraction procedure. After drying, one 
set was reconstituted with AQ LQC and another set with AQHQC. These were 
run in the instrument against AQ LQC + IS and AQHQC + IS (Only Analyte 
with IS) to compare response. The peak areas were compared to study the effect 
of the biological matrix on the drug molecule. 
Formulae: 
Matrix factor: 
   														. .= 	 		
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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	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	
	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			
	
		獦	
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Matrix effect:  
..=  !"	!# !	#!$%&	&'	(#)*	&	+,	&'	-&.$/ 0$#!1$ (	.-%2 ( 	.!3-4  !"	- !2	!# !	#!$%&	&'	(#)*	&	+,	&'	$5 	!6) &).	.!3-4  ×100 
Acceptance Criteria: 
1. Matrix factor should be within 0.85 to 1.15. 
2. %CV of matrix factor should be ≤15%. 
3. Matrix effect should be within ±15%. 
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3.4.4. AUTOSAMPLER CARRYOVER TEST: 
This test is used to check if the response of a high concentration sample is 
carried to the next injection by injecting a blank sample after a high 
concentration sample. 
Procedure: blank (i), LLOQ (ii) and ULOQ(iii) concentrations were injected 
consecutively and the same blank was again re-injected (iv) after ULOQ. The 
peak area ratio of blank was compared between the both injections. 
Formulae: 
For analyte: 
7899:	;<=9 = >89=8	;?8@8A:B=	C@	DA8@E	F2		 − 89=8	;?	8@8A:B=	C@	DA8@E	F1J	K9=8	;?	8@8A:	尷=	C@	LLMN × 100 
For IS: 
									7899:;<=9 = >89=8	;?	QR	C@	DA8@E	F2 − 89=8	;?	QR	C@	DA8@E	F1JK9=8	;?	QR	C@	SLMN 	× 100 
Acceptance Criteria: 
1. For analyte, % carry over should be ≤ 20% of LLOQ area. 
2. For IS it should be ≤ 5% of IS area of ULOQ. 
3.4.5. PRECISION AND ACCURACY BATCHES: 
This test is to ensure the correctness of the value as well as the reproducibility 
of the value in subsequent injections of different samples of same concentration. 
Procedure: One set of CCs and six replicates of each of the QCs were spiked in 
plasma and processed according to the extraction procedure. The peak area of  
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each sample was compared with its replicates and the % deviation of each set 
was checked.  
Formulae: 
The precision (%CVs) is obtained by dividing the standard deviation with the 
mean concentration and multiplying by 100. 
%7U = 	 VW  ×100 
Accuracy is obtained by dividing the calculated concentration of a QC with its 
nominal concentration and multiplying by 100.  
                                      %7U = X	
	
  ×100 
Acceptance Criteria:  
Precision: 
1. The precision should be ≤ 15% for all and  ≤20% for LQC. 
Accuracy: 
1. %CV should be 80-120% for LLOQ and 85-115% for others. 
3.4.6. RECOVERY: 
To determine the amount of drug that can be extracted from the plasma, using 
the optimized extraction procedure. The area obtained in the extracted samples 
is compared with that of the respective aqueous samples. 
Procedure: One set extracted samples were run in P&A batch, from which the 
mean value of area of all the LQCs, MQCs, and HQCs were individually 
divided by the mean area of respective aqueous samples with analyte prepared  
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by serial dilution that were run against extracted samples. The divided value 
gives the recovery. 
Formulae:  
%recovery can be calculated as follows 
%Y = K<=98Z=	89=8	9=[\;@[=	;?	=]B98^B=_	[8`\A=[K<=98Z=	89=8	9=[\;@[=	;?	8ab=;b[	[8`\A=[ × 100 
 Acceptance Criteria: 
 1. According to regulatory guidelines, the maximum recovery allowed is 
115%. Although there is no minimum recovery limit, for practical 
purposes, the lower limit was fixed at 60%. 
  2. %CV should be ≤ 15%. 
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3.5. METHOD VALIDATION: 
Method validation refers to establishing through documented evidence, a high 
degree of assurance that an analytical method will consistently yield results that 
accurately reflect quality characteristics of the product testing. It involves the 
following experiments: 
 System Suitability test 
 Specificity/Selectivity 
 Matrix Effect 
 Auto sampler Carryover Test (ASCOT) 
 P & A batch 
• Intra-day precision & accuracy 
• Inter-day precision & accuracy 
• Ruggedness 
 Recovery  
 Reinjection Reproducibility 
 Stability tests  
3.5.1. SYSTEM SUITABILITY TEST: 
It is timely determination of instrument performance by analysis of a standard 
prior to running an analytical batch. This is to ensure that the complete testing 
system is suitable for the intended application. They are used to verify that the 
resolution and reproducibility of the chromatographic system are adequate for 
the analysis to be done. 
Procedure: Aqueous standard equivalent to middle level of CC standard 
concentration with internal standard was prepared. Six replicate from the same 
vial was injected into the chromatographic device. Mean, Standard Deviation  
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and percentage coefficient of variation for the retention time and area/area ratio 
were calculated. 
Acceptance Criteria: 
 The %CV of peak area ratio and retention time should not be more than 5 
and 15, respectively during system suitability. 
3.5.2. SELECTIVITY/SPECIFICITY: 
Same procedure and acceptance criteria as mentioned above in PRE METHOD 
VALIDATION – 3.4.2. 
3.5.3. MATRIX EFFECT: 
Same procedure, formulae and acceptance criteria as mentioned above in PRE 
METHOD VALIDATION- 3.4.3.  
3.5.4. AUTOSAMPLER CARRYOVER TEST: 
Same procedure, formulae and acceptance criteria as mentioned above in PRE 
METHOD VALIDATION – 3.4.4. 
3.5.5. PRECISION AND ACCURACY BATCHES: 
Validation is carried out using a minimum of three acceptable batches. The 
precision was determined by calculating percentage %CV at each concentration 
level of QC sample and the accuracy was determined by calculating the 
percentage of nominal value at each concentration level of QC samples. 
Procedure: The procedure is same as mentioned above in PRE-METHOD 
VALIDATION – 3.4.5. 
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Formulae:  
The precision (%CV’s) is obtained by:   
   %7U = 	 VW  ×100 
 Accuracy (%nominal) is obtained by  
%7U = =8@	^;@^=@B98BC;@@;`C@8A	^;@^=@B98BC;@ × 100 
Intra batch: 
To obtain within-batch data precision, the mean, standard deviation and 
%CV of each concentration in the same P&A was calculated. 
Inter batch: 
To obtain between-batch data precision, the global mean, standard deviation 
and %CV from all acceptable batches for each QC concentration were 
calculated.  
To obtain within-batch data accuracy, the mean of respective QC was 
calculated by dividing with its nominal concentration and multiplied by 100. 
To obtain between-batch data accuracy, the global mean of respective QC 
was calculated and divided with its nominal concentration and multiplied by 
100. 
Ruggedness: 
One P&A batch was performed by employing the same instrument with 
different analyst and alternatively performed on different instrument of same 
make. 
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Acceptance criteria: 
• Precision 
The within-batch and between-batch precision for the QC’s (LQC, 
INTQC, and MQC & HQC) and LOQQC should be ≤15% and 
≤20% using a minimum of three P&A batches. 
• Accuracy 
The mean of within and between-batch accuracy should be 85-
115% of the nominal value for QCs (80–120% of the nominal 
value for LOQQC). 67% of total QCs per level must be 85–115% 
of the nominal value except for LOQQC, where it should be 80-
120% of the nominal value. 
 
3.5.6. RE-INJECTION REPRODUCIBILITY: 
Re-injection reproducibility is a test to ensure consistency in the values obtained 
during repeated injection of same samples. 
Procedure: After analysis of any acceptable P&A batch, the CC and QC 
samples were re-injected at least 3hours from the completion of the 
corresponding P&A batch. The back-calculated concentrations of the high and 
low re-injected QC samples using calibration curve standards of the originally 
run P&A batch were calculated. 
Acceptance Criteria: 
1. The mean of back calculated values should be between 85 to 115% 
of the nominal concentration and the %CV should be ≤ 15%. 67% 
of total QCs per level must be 100±15% nominal value. 
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2. Ratio of means should be within 1.0±0.15 while comparing the 
mean of back calculated values against the mean of values obtained 
from an original injection. 
3.5.7. RECOVERY: 
Same procedure, formulae and acceptance criteria as mentioned above in PRE 
METHOD VALIDATION – 3.4.6. 
 3.5.8. STABILITY: 
Evaluation of stability should be carried out to ensure that every step taken 
during sample preparation and sample analysis, as well as the storage conditions 
used do not affect the concentration of the analyte. The following are the 
common stability tests conducted in method validation: 
1. Stock Solution stability          
• Short Term stock solution stability 
• Long Term stock solution stability 
2. Stability in biological matrix            
• Bench Top stability 
• Freeze Thaw stability 
• Long Term stability 
• Blood stability 
3. In process/Post processing stability 
• Autosampler/Wet Extract stability 
• Dry Extract stability 
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3.5.8.1. Stock solution stability 
The stability test for the standard stock solution must be done at the same 
temperature, container and solvent as that to be used for the study. The time 
period should be at least 6 hours 
3.5.8.2. Short term matrix stability 
This must be evaluated following the storage under laboratory conditions used 
for sample work-up for a period of e.g. 6 h to 24 h, and compared with data 
from the same samples prepared and analyzed without delay. 
3.5.8.3. Long term stability 
This is done to assess whether the analyte is stable in the plasma matrix under 
the sample storage conditions for the time period required for the samples 
generated in a clinical study to be analyzed. 
3.5.8.4. Freeze -thaw stability 
This stability test is done to ensure that the sample remains stable after it is 
subjected to multiple freeze-thaw cycles in the process of the study.  
3.5.8.5. Bench Top Stability: 
This is evaluated to confirm that the analyte should not degrade its processing 
(preparation, extraction) period to the analysis.  
 
Procedure for analyte: Replicate stability samples and 6 sets of LQC and HQC 
samples from intended storage temperature at each concentration were allowed 
to remain on the bench-top for the period of 4-24 hours for which stability is to 
be assessed. It is left at room temperature/ ice cold water bath for a minimum of 
6 hours and processed. These samples were injected into the instrument. The 
accuracy and precision of QC samples against freshly spiked CC standards were 
calculated and compared with freshly spiked comparison QC samples. 
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Internal Standard: Six replicate of screened pooled plasma were aliquoted and 
IS was added. The samples were kept on bench for intended duration. Six 
replicate of the screened pooled plasma were freshly aliquoted, internal standard 
was added and were mixed by vortexing. Both IS stability and comparison 
samples were processed.  
Calculation: 
%	nominal	against	CS	 = 	n=8E	89=8	;?	C@^bD8B=_	[8`\A=	n=8E	89=8	;?	@;9`8A	[8`\A= 	× 100 
Acceptance Criteria: 
The % stability should be between 85 to 115%. 
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4. RESULTS AND DISCUSSION: 
 
4.1. CHROMATOGRAMS 
Chromatograms are obtained as a result of the detection of the relevant 
molecule by the LC-MS/MS instrument. It shows a plot of the response of the 
instrument against the time. The response is proportional to the concentration of 
the sample used and the peak forms at the retention time which is characteristic 
of a molecule. In the given chromatograms, the retention time and peak area are 
given below the molecule name.  
4.1.1. SYSTEM SUITABILITY: 
Aqueous standard refers to a solution of the analyte in solvent and not plasma. 
These standards are used to set an expected concentration for the extracted 
samples. A middle concentration of the analyte was injected as aqueous 
standard in order to check whether the system is suitable for the selected 
analyte. Sharp and singular peaks were obtained at the expected retention times 
of each molecule, which confirmed the stability and suitability of the instrument 
to be used. 
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Fig - 13:   Chromatogram of SS (ASEN & IS)  
 
 
Fig - 14: Chromatogram of SS (DES ASE & IS) 
 
4.1.2. LINEARITY 
Aqueous standards with increasing concentrations were prepared in the range of 
0.1080 – 35.314 ng/mL(ANALYTE) and 0.1060 – 34.47 ng/mL 
(METABOLITE) (A - H). These concentrations, called the calibration curve 
standards or CCs must give a linear curve when plotted for response against the 
concentration. Only if this linearity is passed, the method can be developed in 
that concentration range. Based on the criteria mentioned above, the aqueous 
standards were prepared and injected. The response obtained was plotted 
against the concentration of the analyte. The linearity passed for both Asenapine 
and Metabolite calibration curves by excluding two non-consecutive points out 
of the eight. The curve was fit to the equation: 
y = mx + c, 
 with a weighting factor of 1/x2. The slope and intercept of ASE and DES ASE 
were found to be 0.374, 0.0114 and 0.378, 0.00858 respectively. The correlation  
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coefficient r was 0.9992 and 0.9958 for Asenapine and N-Desmethyl Asenapine 
respectively. This curve serves as the standard graph to determine the expected 
concentration of extracted samples of the analyte. 
 
 
Fig- 15: Linearity curve for ASEN and DES ASE 
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4.1.3. STANDARD BLANK: 
Blank refers to either the solvent/ mobile phase alone (aqueous blank) or plasma 
alone (extracted blank), without any analyte spiked in it. A blank sample has to 
be run in order to check the baseline stability and ensure that there is no 
contamination in the solvent or plasma. In order to expect minimum noise, the 
response should be less than e4.The blank samples injected gave no peak, 
indicating the absence of any contamination. The baseline was found to be 
stable. The responses obtained were e4, e2, e4 and e3 for various blank injections. 
 
Fig- 16: Chromatogram for Blank (ASEN & IS) 
 
Fig- 17: Chromatogram for Blank (DES ASE & IS) 
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4.1.4. STANDARD ZERO: 
Zero refers to the blank solution along with the internal standard alone. This is 
used to check for any IS contamination and also to determine the IS area 
obtained. The zero samples gave no peak for the analyte molecules at their 
retention times. It produced a sharp peak at the IS retention times 2.24 for IS.  
 
Fig- 18: Chromatogram for Zero (ASEN & IS) 
 
Fig- 19: Chromatogram for Blank (DES ASEN & IS) 
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4.1.5. QUALITY CONTROL CURVES: 
Quality controls are standards of lower to higher concentrations within the 
selected range. The responses of these aqueous standards provide the expected 
concentration in extracted / plasma samples. The chromatograms are obtained in 
which the peak forms at the retention time of the molecule and the peak area 
was found to increase with the concentration. Five concentrations were used as 
the quality controls (LOQQC, LQC, INTQC, MQC, HQC).   
4.1.5.1. LOWEST OF QUANTIFICATION QUALITY CONTROL(LOQQC)  
 
Fig- 20: Chromatogram for LOQQC (ASEN & IS) 
 
Fig- 21: Chromatogram for LOQQC (DES ASE & IS) 
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4.1.5.2. LOWER QUALITY CONTROL (LQC): 
 
 
Fig- 22: Chromatogram for LQC (ASEN & IS) 
 
Fig- 23: Chromatogram for LQC (DES ASE & IS) 
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4.1.5.3. INTERMEDIATE QUALITY CONTROL (INTQC): 
 
 
Fig- 24: Chromatogram for INTQC (ASEN & IS) 
 
Fig- 25: Chromatogram for INTQC (DES ASE & IS)  
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4.1.5.4. MIDDLE CONCENTRATION: 
 
Fig- 26: Chromatogram for MQC (DES ASE & IS) 
 
Fig- 27: Chromatogram for MQC (DES ASE & IS) 
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4.1.5.5. HIGHEST QUALITY CONTROL (HQC) 
 
Fig- 28: Chromatogram for MQC (ASEN & IS) 
 
Fig- 29: Chromatogram for MQC (DES ASE & IS) 
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4.2. RESULT TABLES 
 
4.2.2. SPECIFICITY/ SELECTIVITY TEST: 
Specificity and selectivity test ensures that only the relevant molecule is 
detected and there is no interference from any other molecule in the plasma. In 
table (7) and (8) first column indicates plasma lot number used. The specificity 
is tested with the blank plasma, under which all lots show no peak area for 
analyte and metabolite as Asenapine is an exogeneous drug. Selectivity is given 
under the samples containing LLOQ concentration of the analyte, where the 
obtained peak areas are given for the analyte , metabolite and IS. % interference 
in blank is a comparison of the blank and LLOQ areas for the analyte/ 
metabolite and IS. 
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Table-7: Result of Specificity/ selectivity (ASEN) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma 
lot ID 
Specificity 
(blank) 
Selectivity 
(Spiked LLOQ) 
% Interference in 
Blank 
Area 
Ratio 
S/N Ratio 
(≥5) 
Analyte IS 
peak 
Analyte IS peak Analyte 
(≤20%) 
IS (≤5%) Analyte/ 
IS 
Analyte 
1 0 0 3167 110590 0.0000 0.0000 0.0286 217.764 
2 0 0 3305 109492 0.0000 0.0000 0.0302 242.884 
3 0 0 3390 109914 0.0000 0.0000 0.0308 289.048 
4 0 0 3479 107712 0.0000 0.0000 0.0323 205.072 
5 0 0 3360 111424 0.0000 0.0000 0.0302 337.115 
6 0 0 3515 105480 0.0000 0.0000 0.0333 217.603 
7 0 0 3811 112549 0.0000 0.0000 0.0339 387.889 
8 0 0 3590 120868 0.0000 0.0000 0.0297 207.186 
9 0 0 3255 108073 0.0000 0.0000 0.0301 321.977 
10 0 0 3616 112664 0.0000 0.0000 0.0321 222.191 
11 0 0 3575 110119 0.0000 0.0000 0.0325 199.544 
12 0 0 3677 105788 0.0000 0.0000 0.0348 280.325 
13 0 0 3147 105127 0.0000 0.0000 0.0299 248.143 
14 0 0 3039 109003 0.0000 0.0000 0.0279 275.348 
15 0 0 3506 103712 0.0000 0.0000 0.0338 321.074 
16 (H) 0 0 3234 106429 0.0000 0.0000 0.0304 249.751 
 MEAN 0.00000 0.00000 0.03128 
 SD 0.002010 
%CV 6.43 
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Table-8: Result of Specificity/ selectivity (DES ASE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasma 
lot ID 
Specificity 
(blank) 
Selectivity (Spiked 
LLOQ) 
% Interference in 
Blank 
Area Ratio S/N Ratio 
(≥5) 
Metabolite IS 
peak 
Metabolite IS 
peak 
Metabolite 
(≤20%) 
IS 
(≤5%) 
Metabolite/ 
IS 
Metabolite 
1 0 0 2979 110599 0.0000 0.0000 0.0269 217.477 
2 0 0 3009 109492 0.0000 0.0000 0.0275 226.019 
3 0 0 2809 109914 0.0000 0.0000 0.0256 239.894 
4 0 0 3310 107712 0.0000 0.0000 0.0307 295.967 
5 0 0 3224 111424 0.0000 0.0000 0.0289 182.073 
6 0 0 2874 105480 0.0000 0.0000 0.0272 223.470 
7 0 0 3352 112549 0.0000 0.0000 0.0298 246.484 
8 0 0 3429 120868 0.0000 0.0000 0.0284 169.512 
9 0 0 3053 108073 0.0000 0.0000 0.0283 209.646 
10 0 0 3428 112664 0.0000 0.0000 0.0304 230.863 
11 0 0 3337 110119 0.0000 0.0000 0.0303 235.131 
12 0 0 3069 105788 0.0000 0.0000 0.0290 249.241 
13 0 0 3139 105127 0.0000 0.0000 0.0299 300.303 
14 0 0 3056 109003 0.0000 0.0000 0.0280 303.736 
15 0 0 2958 103712 0.0000 0.0000 0.0285 211.800 
16(H) 0 0 3067 106429 0.0000 0.0000 0.0288 255.619 
 MEAN 0.00000 0.00000 0.02864  
 SD 0.001402 
%CV 4.90 
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The analyte and metabolite interference were ≤ 20% and IS interference was ≤ 
5%. The area ratio was determined as the ratio of analyte area to IS area. The 
S/N ratio was obtained by comparing the original peak (signal) to the baseline 
interferences (noise). It was found to be ≥ 5. 
The specificity and selectivity were found to be satisfactory with all the values 
within the expected acceptance criteria. 
Model Calculation: 
%	C@B=9?=9=@^=	C@	DA8@E = 	FA8@E	89=8LLMN	89=8 	× 100 
K9=8	98BC; = 	K@8A:B=>;9J=B8D;ACB=	89=8QR	89=8  
For lot no. 1: 
%	C@B=9?=9=@^=		 ◌ܼ@	DA8@E = 02979	× 100 = 0 
K9=8	98BC; = 2979110599 = 0.0269 
RB8@_89_	_=<C8BC;@, t = uvw >0.0269− 0.02864Jz = 0.001402 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	 0.0014020.02864 × 100 = 4.90 
4.2.3. MATRIX EFFECT: 
Matrix effect is tested in order to ensure that the plasma has no effect on the 
analyte and metabolite. It compares the spiked sample area to the aqueous 
sample area and the area ratio is calculated for both aqueous and spiked 
samples. The calculations were done individually for the LQC and the HQC 
concentrations. The matrix factor was determined by the given formula, which 
gives the extent to which the plasma affects the peak area obtained. 
63 
 
 
Table – 9: Result of Matrix Effect (ASEN- LQC)  
 
 
Plasma 
Lot No. 
Aqueous Sample Spiked Sample Area Ratio  
 
Matrix 
Factor Analyte 
area 
IS Area Analyte 
Area 
IS Area Aqueous 
Sample 
Spiked 
Sample 
1 12707 144637 12618 145645 0.0879 0.0866 0.98 
2 11927 141006 12073 144099 0.0846 0.0838 0.95 
3 12252 141279 11944 143886 0.0867 0.0830 0.94 
4 12614 144040 11909 145977 0.0876 0.0816 0.93 
5 12939 143733 12485 139666 0.0900 0.0894 1.02 
6 12832 141418 11588 141619 0.0907 0.0818 0.93 
 7 (H)*   11765 136007  0.0865 0.98 
 
 MEAN 0.08792 0.084673 0.9614 
SD 0.033381 
%CV 3.47 
 
Table – 10: Result of Matrix Effect (ASEN- HQC) 
 
Plasma 
Lot 
No. 
Aqueous Sample Spiked Sample Area Ratio  
Matrix 
Factor Analyte 
area 
IS Area Analyte 
Area 
IS Area Aqueous 
Sample 
Spiked 
Sample 
1 900681 136577 909231 134898 6.5947 6.7401 1.02 
2 907043 137813 905281 137409 6.5817 6.5882 0.99 
3 905590 133659 917562 135630 6.7754 6.7652 1.02 
4 893690 136727 901117 136366 6.5363 6.6081 1.00 
5 915618 137210 900857 138650 6.6731 6.4973 0.98 
6 905342 136088 893063 137730 6.6526 6.4842 0.98 
        7 
(H)* 
  917182 138626  6.6162 1.00 
 MEAN 6.63563 6.61419 0.99857 
SD 0.016762 
%CV 1.68 
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Table – 11: Result of Matrix Effect (DES ASE- LQC) 
 
 
Plasma Lot 
No. 
Aqueous Sample Spiked Sample Area Ratio  
 
Matrix 
Factor 
Analyte 
area 
IS Area Analyte 
Area 
IS Area Aqueous 
Sample 
Spiked 
Sample 
1 10002 144637 9901 145645 0.0692 0.0680 0.99 
2 9863 141006 9644 144099 0.0669 0.0669 0.98 
3 9317 141279 9158 143886 0.0659 0.0636 0.93 
4 9927 144040 9499 145977 0.0689 0.0651 0.95 
5 10018 143733 9568 139666 0.0697 0.0685 1.00 
6 9466 141418 9424 141619 0.0669 0.0665 0.97 
        7 (H)*   9928 136007  0.0730 1.07 
 
 MEAN 0.06842 0.06737 0.98429 
SD 0.044668 
%CV 4.54 
 
Table- 12: Result of Matrix Effect (DES ASE- HQC) 
 
 
Plasma 
Lot No. 
Aqueous Sample Spiked Sample Area Ratio  
 
Matrix 
Factor 
Analyte 
area 
IS Area Analyte 
Area 
IS Area Aqueous 
Sample 
Spiked 
Sample 
1 731686 136577 726008 134898 5.3573 5.3819 0.99 
2 756329 137813 728727 137409 5.4881 5.3034 0.98 
3 724736 133659 706483 135630 5.4223 5.2089 0.96 
4 749198 136727 707059 136366 5.4795 5.1850 0.96 
5 729702 137210 723883 138650 5.3181 5.2209 0.96 
6 745773 136088 712845 137730 5.4801 5.1757 0.95 
       7 (H)*   713542 138626  5.1473 0.95 
 
 MEAN 5.42423 5.23187 0.96429 
SD 0.015119 
%CV 1.57 
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The standard deviation and coefficient of variation were calculated for the 
matrix factor. It was found that the matrix factor was between 0.85 and 1.15 for 
all samples. The %CV was 3.47 AND 4.54 for analyte and metabolite, which is 
≤ 15. Hence the acceptance criteria (Page-38) have been satisfied and the matrix 
effect is negligible. 
Model Calculation: 
K9=8	98BC; = 	K@8A:B=	89=8QR	89=8  
8B9C]	?8^B;9 = 	 \=8E	89=8	98BC;	;?	[\CE=_	[8`\A=[	\=8E	89=8	98BC;	;?	8ab=;b[	[8`\A=[ 
RB8@_89_	_=<C8BC;@, t = {1| >] − }Jz 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	t} × 100 
For lot no. 1: 
K9=8	98BC; = 	 12707144637 = 	0.0879 
 
8B9C]	?8^B;9 = 	0.08660.0879 = 	0.98 
RB8@_89_	_=<C8BC;@, t = {17 >0.98 − 0.9614Jz = 	0.033381 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	0.0333810.9614 × 100 = 3.47 
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4.2.4.ALL SAMPLE CARRY OVER TEST: 
Auto sampler carry over test is done to ensure that the injection of a high 
concentration sample does not affect the consecutive injection of blank 
samples.A blank, LLOQ, ULOQ were injected consecutively and the blank was 
then re-injected. 
 
Table – 13: Result of ASCOT (ASEN) 
 
 
 
  
 
 
Table – 14: Result of ASCOT (DES ASE) 
Sample ID Analyte Peak Area IS Peak Area 
Extracted Blank 0 0 
Extracted LLOQ+IS 3286 114743 
Extracted ULOQ+IS 1312376 134401 
Extracted Blank 0 0 
% Carry Over 0.00 0.0 
 
Sample ID Analyte Peak Area IS Peak Area 
Extracted Blank 0 0 
Extracted LLOQ+IS 4419 114743 
Extracted ULOQ+IS 1845907 134401 
Extracted Blank 0 0 
% Carry Over 0.00 0.0 
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The re-injected blank was found to show a peak area ≤ 20 % of the LLOQ for 
the analyte and metabolite ≤ 5% of the ULOQ for the IS. [Table (13&14)]. 
Hence the carry over in the instrument was found negligible. 
Model Calculation: 
%	7899:	;<=9 = 	]B98^B=_	DA8@E	C@=^B=_	2@_	BC`=	LLMN	[8`\A= × 100 
For Asenapine analyte peak area: 
%	7899:	;<=9 = 	 04419 × 100 = 0 
 
4.2.4. PRECISION AND ACCURACY BATCH: 
The precision and accuracy test is done to determine how exact and correct the 
values obtained are. It is calculated separately for the CCs and QCs. The actual 
concentration in table (15) and (16) refers to the value of the aqueous standards. 
The calculated concentration is the concentration obtained for spiked samples. 
Table shows only single values for the CCs for which only a single set of spiked 
samples were used. The six calculated concentrations for the extracted samples 
in table below were taken on average and compared to the actual concentration 
by calculating the % nominal which indicates the accuracy. The coefficient of 
variation indicates the precision of the values. 
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% nominal for all the samples was found to be between 85 and 115%.  %CV for 
all the samples was found to be ≤ 15% as per the acceptance criteria (Page-40). 
Hence the PA batch was passed for the given acceptance criteria. 
Model Calculation: 
RB8@_89_	_=<C8BC;@, t = {1| >] − }Jz 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	t} × 100 
%	@;`C@8A = 	`=8@	;?	^8A^bA8B=_	<8Ab=[8^Bb8A	<8Ab=[ 	× 100 
INTER AND INTRA DAY PRECISION: 
Similarly inter and intra day P&A batch were also performed inorder to find the 
Precision, Accuracy and Ruggedness. 
Table – 17: Result of Inter and Intra P&A Batch (ASEN) 
QC ID LOQQC LQC INTQC MQC HQC 
Act Conc (ng/mL) 0.1100 0.2980 2.5520 12.7640 25.5280 
 
Calculated 
Concentration (ng/mL) 
 
PA – 02 
 
07 Mar 13 
0.1306 0.3146 2.6204 12.7453 26.4243 
0.1150 0.3066 2.5636 13.0620 26.8256 
0.1215 0.2927 2.5248 13.1402 25.7862 
0.1250 0.2790 2.5839 13.2403 25.9268 
0.1251 0.2870 2.5874 13.1796 26.1853 
0.1262 0.2971 2.5970 12.7074 26.1746 
Mean 0.12390 0.29617 2.57952 13.01247 26.22047 
SD 0.005250 0.012963 0.032575 0.229371 0.370379 
%CV 4.24 4.38 1.26 1.76 1.41 
%Nominal 112.64 99.38 101.08 101.95 102.71 
 
Calculated 
0.1136 0.3149 2.5407 13.1206 25.2332 
0.1224 0.3055 2.4366 13.1042 25.4600 
71 
 
Concentration (ng/mL) 
 
PA – 03 
 
07 Mar 13 
0.1188 0.3007 2.5912 12.7639 25.7128 
0.1179 0.3072 2.4733 12.7392 26.0920 
0.1200 0.3045 2.5011 12.9900 25.8031 
0.1111 0.3004 2.5329 13.3425 26.7973 
Mean 0.11730 0.30553 2.51263 13.01007 25.84973 
SD 0.004196 0.005316 0.054465 0.230634 0.549455 
%CV 3.58 1.74 2.17 1.77 2.13 
%Nominal 106.64 102.53 98.46 101.93 101.26 
 
 
Calculated 
Concentration (ng/mL) 
 
PA – 04 
 
08 Mar 13 
0.4229* 0.2888 2.5262 12.6272 23.1539 
0.1007 0.4217* 2.5225 12.3875 25.1890 
0.1097 0.2823 2.5356 12.4267 27.5285 
0.1038 0.2889 2.5629 12.4556 24.8686 
0.1094 0.2635 2.6519 12.5785 24.3997 
0.0927 0.3083 2.5752 12.6713 26.6160 
Mean 0.10326 0.28636 2.56238 12.52447 25.29262 
SD 0.007027 0.016069 0.048570 0.116700 1.569233 
%CV 6.81 5.61 1.90 0.93 6.20 
%Nominal 93.87 96.09 100.41 98.12 99.08 
 
 
Calculated 
Concentration (ng/mL) 
 
PA – 05 
 
09 Mar 13 
0.1005 0.3064 2.5650 13.5058 25.5754 
0.1232 0.3231 2.6428 12.8194 26.5014 
0.0964 0.2844 2.6140 13.4811 24.9675 
0.0816 0.3038 2.5029 13.0308 25.8194 
0.1028 0.3198 2.5479 13.4079 25.1698 
0.1176 0.2981 2.4359 12.9267 25.4783 
Mean 0.10368 0.30593 2.55142 13.19528 25.58530 
SD 0.015008 0.014260 0.075050 0.304564 0.540353 
%CV 14.47 4.66 2.94 2.31 2.11 
%Nominal 94.26 102.66 99.98 103.38 100.22 
 
Note*: LOQQC-25 & LQC-26 were not included in the calculation due to increase in 
analyte peak area and decrease in internal standard area observed. 
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Table – 18: Result of Inter and Intra P&A Batch (DES ASE) 
QC ID LOQQC LQC INTQC MQC HQC 
Act Conc (ng/mL) 0.1080 0.2920 2.5080 12.5440 25.0860 
 
Cal. Conc (ng/mL) 
 
PA – 01 
 
06 Mar 13 
0.1275 0.2883 2.4527 12.6913 25.0637 
0.1126 0.3299 2.6032 12.9009 26.1374 
0.1208 0.3279 2.6023 12.1371 24.5664 
0.1133 0.3060 2.3402 12.1978 23.9863 
0.1220 0.3094 2.3163 12.1279 24.5801 
0.1224 0.3039 2.5131 11.9441 23.5757 
Mean 0.11977 0.31090 2.47130 12.33318 24.65160 
SD 0.005761 0.15723 0.124791 0.374394 0.893307 
%CV 4.81 5.06 5.05 3.04 3.62 
%Nominal 110.90 106.47 98.54 98.32 98.27 
 
Calculated 
Concentration 
(ng/mL) 
 
PA – 02 
07 Mar 13 
0.1192 0.2716 2.3016 11.3075 23.6310 
0.1077 0.2774 2.2975 11.4470 25.3775 
0.1061 0.2304 2.1778 11.3394 22.7298 
0.0940 0.2338 2.2235 11.0628 22.8670 
0.1204 0.2500 2.3368 10.6648 22.2770 
0.1057 0.2505 2.1376 11.0467 25.0590 
Mean 0.10885 0.25228 2.24580 11.14470 23.65688 
SD 0.009796 0.019146 0.078608 0.283694 1.289543 
%CV 9.00 7.59 3.50 2.55 5.45 
%Nominal 100.79 86.40 89.55 88.84 94.30 
 
Calculated 
Concentration 
(ng/mL) 
 
PA – 03 
07 Mar 13 
0.1308 0.2856 2.4967 12.8099 24.8484 
0.1070 0.3087 2.4203 12.7620 24.6048 
0.1091 0.2856 2.5655 11.6574 23.7209 
0.1030 0.2851 2.4067 12.1180 23.7001 
0.1083 0.2809 2.3713 11.9956 22.9256 
0.1094 0.2728 2.4367 11.7287 23.8418 
Mean 0.11127 0.28645 2.44953 12.17860 23.94027 
SD 0.009850 0.011962 0.070210 0.500023 0.694458 
%CV 8.85 4.18 2.87 4.11 2.90 
%Nominal 103.02 98.10 97.67 97.09 95.43 
 
Calculated 
Concentration 
(ng/mL) 
 
PA – 04 
08 Mar 13 
0.4141 0.2637 2.5264 11.3724 21.2046 
0.0911 0.3844 2.4378 11.3625 24.0112 
0.1039 0.2690 2.5632 11.5323 27.3929 
0.0940 0.2569 2.3825 12.0130 24.2429 
0.0835 0.2917 2.6219 11.9468 22.9111 
0.0966 0.2401 2.4872 11.9982 26.6316 
Mean 0.14720 0.28430 2.50317 11.70420 24.39905 
SD 0.130924 0.051841 0.086406 0.315293 2.303942 
%CV 88.94 18.23 3.45 2.69 9.44 
%Nominal 136.30 97.36 99.81 93.31 97.26 
Calculated 
Concentration 
(ng/mL) 
 
PA – 05 
0.1186 0.3052 2.6631 12.8722 23.4465 
0.1278 0.3836 2.8007 12.4424 23.5755 
0.1075 0.2810 2.6746 13.4837 23.1479 
0.1275 0.3035 2.4097 12.6551 22.6159 
0.1224 0.2769 2.4680 11.9816 22.4846 
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09 Mar 13 0.1265 0.3357 2.5480 11.4625 22.3437 
Mean 0.12172 0.31432 2.59402 12.48292 22.93568 
SD 0.007818 0.039919 0.154471 0.703842 0.523740 
%CV 6.42 12.70 5.61 5.64 2.28 
%Nominal 112.70 107.64 103.43 99.51 91.43 
 
% nominal for all the samples was found to be between 85 and 115%.  %CV for 
all the samples was found to be ≤ 15% as per the acceptance criteria (Page-46). 
Hence the inter and intra day PA batch was passed for the given acceptance 
criteria. 
4.2.5. REINJECTION REPRODUCIBILITY: 
The RIR test is conducted to ensure repeatability of the experiment after a 
period of time. A set of six samples each of LQC and HQC concentrations used 
for a PA batch were injected after 31.75hours of completion of a PA batch. The 
values of actual and calculated concentrations obtained for the two injections 
were compared and the mean, SD, %CV, %nominal and ratio of means were 
calculated in Table(19&20). 
Table – 19: Result of  RIR (ASEN)  
 
Batch ID 
 
Reinjection Reproducibility 
PA-03 Samples Reinjected Samples (31.75 hrs) 
LQC HQC LQC HQC 
Actual Conc(mg/mL) 0.2980 25.5280 0.2980 25.5280 
 
 
 
Calc. Conc(ng/mL) 
 
0.3149 25.2332 0.3114 24.9602 
0.3055 25.4600 0.2952 24.7545 
0.3007 25.7128 0.3079 25.4905 
0.3072 26.0920 0.2908 25.4115 
0.3045 25.8031 0.2987 25.4004 
0.3004 26.7973 0.3049 25.2369 
Mean 0.30553 25.84973 0.30148 25.20900 
SD 0.005316 0.549455 0.007906 0.291936 
%CV 1.74 2.13 2.62 1.16 
%Nominal 102.53 101.26 101.17 98.75 
Ratio of Means   0.99 0.98 
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Table – 20: Result of  RIR (DES ASE) 
 
Batch ID 
 
 
Reinjection Reproducibility 
PA-03 Samples Reinjected Samples (31.75 hrs) 
 LQC HQC LQC HQC 
Act. 
Conc(mg/mL) 
0.2980 25.5280 0.2980 25.5280 
 
 
Calc. 
Conc.(ng/mL) 
 
 
0.2856 24.8484 0.2862 24.9608 
0.3087 24.6048 0.3053 24.7556 
0.2856 23.7209 0.2912 25.4912 
0.2851 23.7001 0.2935 25.4123 
0.2809 22.9256 0.2987 25.4012 
0.2728 23.8418 0.3056 25.2429 
Mean 0.28645 23.94027 0.30163 25.21000 
SD 0.011962 0.694458 0.007913 0.292136 
%CV 4.18 2.90 2.74 1.36 
%Nominal 98.10 95.43 102.12 99.65 
Ratio of Means   0.99 0.99 
 
The mean values were found to be between 85 and 115% of the actual 
concentrations for all the samples. The %CV was ≤ 15% for all samples. The 
ratio of means was within 1.0 ± 0.15. Hence the RIR test was passed. 
Model Calculation: 
RB8@_89_	_=<C8BC;@, t = {1| >] − }Jz 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	t} × 100 
75 
 
%	@;`C@8A = 	`=8@	;?	^8A^bA8B=_	^;@^=@B98BC;@8^Bb8A	^;@^=@B98BC;@ 	× 100 
Y8BC;	;?	`=8@[ = `=8@	;?	=]B98^B=_	[8`\A=	`=8@	;?	8ab=;b[	[8`\A=  
For ASENAPINE  aqueous LQC sample: 
RB8@_89_	_=<C8BC;@, t = uv >0.3149 − 0.30553Jz = 0.005316 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	 .v. × 100 = 1.74 
%	@;`C@8A = 	 ..z 	× 100 = 102.53  
Y8BC;	;?	`=8@[ = 0.301480.30553 = 0.99 
4.2.6. RECOVERY: 
Recovery refers to the response from the amount of drug that can be separated 
from the spiked plasma as compared to the aqueous sample of the drug. It is the 
deciding factor in selection of a method of extraction. 
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Table – 21: Result of Recovery (ASEN) 
Quality Control 
Samples ID 
Aqueous 
Analyte Area 
Extracted 
Analyte Area 
 
 
 
 
LQC 
16894 15333 
17438 14793 
18034 15646 
17777 14983 
16901 14569 
17691 14181 
Mean 17456 14918 
SD 473 527 
%CV 2.71 3.53 
%Recovery 85.46 
 
 
 
MQC 
747561 626312 
780634 612935 
748360 590844 
750097 631328 
769826 568301 
781737 601957 
Mean 783036 605280 
SD 16296 23522 
%CV 2.14 3.89 
%Recovery 79.33 
 
 
 
HQC 
1608663 1199514 
1650385 1228869 
1650090 1230270 
1671796 1375831 
1612254 1310097 
1654997 1268525 
Mean 1641364 1268851 
SD 25244 64870 
%CV 1.54 5.11 
%Recovery 77.30 
Recovery Result 
LQC 85.46 
MQC 79.33 
HQC 77.30 
MEAN 80.70 
SD 4.25 
%CV 5.26 
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Table – 22: Recovery of Recovery (DES ASE) 
Quality Control 
Samples ID 
Aqueous 
Analyte Area 
Extracted 
Analyte Area 
 
 
 
 
LQC 
12107 10652 
12095 11548 
12513 11983 
12275 10731 
12328 10993 
12645 10428 
Mean 123270 11056 
SD 219 595 
%CV 1.78 5.38 
%Recovery 89.69 
 
 
 
MQC 
561710 448976 
557012 442950 
548951 416296 
551383 432435 
564679 397408 
586655 407794 
Mean 561732 424310 
SD 13584 20409 
%CV 2.42 4.81 
%Recovery 75.54 
 
 
 
HQC 
1162544 860922 
1162065 897717 
1163929 855382 
1162055 904968 
1166202 896729 
1171397 830364 
Mean 1164699 874347 
SD 3641 29864 
%CV 0.31 3.42 
%Recovery 75.07 
Recovery Result 
LQC 89.69 
MQC 75.54 
HQC 75.07 
MEAN 80.10 
SD 8.31 
%CV 10.37 

78 
 
 
Table – 23: Result of Recovery (ASEN 13 C D3) 
Quality Control Samples ID Aqueous Analyte 
Area 
Extracted Analyte 
Area 
 
 
LQC 
149857 143381 
154406 135113 
152794 141122 
151945 135786 
159934 137495 
157881 132908 
 
 
 
MQC 
163389 131842 
175894 127957 
166611 127832 
170247 132126 
172586 122125 
175713 127247 
 
 
 
HQC 
164247 127955 
167392 127940 
171296 129706 
168886 140545 
165318 135900 
167788 131206 
MEAN 164232 
 
132677 
 
The % recovery was greater than 60% and less than 115% for all samples. The 
% CV was less than 15%. Hence the acceptance criteria for recovery (Page-41) 
were satisfied.            
Model Calculation: 
RB8@_89_	_=<C8BC;@, t = {1| >] − }Jz 
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%	^;=??C^C=@B	;?	<89C8BC;@ = 	t} × 100 
 
%	9=^;<=9: = `=8@	=]B98^B=_	\=8E	89=8	`=8@	8ab=;b[	\=8E	89=8 	× 100 
 
For ASENAPINE aqueous sample LQC: 
RB8@_89_	_=<C8BC;@, t = uv >16894 − 17456Jz = 473 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	 47317456 × 100 = 	2.71 
%	9=^;<=9: = 1491817456	× 100 = 	. % 
 
4.2.7. BENCH TOP STABILITY: 
Stability tests are conducted to ensure that the sample is stable under various 
conditions and time period. Long term stability test was conducted by injecting 
one set of LQC and HQC concentrations immediately and two sets of LQC and 
HQC samples after 55days at -30ºC and -70ºC respectively. Aqueous samples 
were injected once and extracted were injected six times. The mean, SD, %CV, 
% nominal and % nominal against CS sample. 
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%nominal was found to be between 85 and 15% for all cases. Thus the 
acceptance criteria (Page-48) were satisfied. Hence the drug passed the stability 
test and is considered suitable for injection even after long periods of 
incubation. 
Model Calculation: 
RB8@_89_	_=<C8BC;@, t = {1| >] − }Jz 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	t} × 100 
%	@;`C@8A = 	`=8@	;?	^8A^bA8B=_	^;@^=@B98BC;@8^Bb8A	7;@^=@B98BC;@ 	× 100 
For ASENAPINE sample LQC: 
RB8@_89_	_=<C8BC;@, t = uv >0.3000 − 0.29177Jz = 0.009022 
%	^;=??C^C=@B	;?	<89C8BC;@ = 	0.0090220.29177 × 100 = 3.09 
%	@;`C@8A = 	0.291770.2980 	× 100 = 	97.91 
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     SUMMARY 
Internal Standard Used : the deuterated compound of the analyte – Asenapine 
13C D3 to reduce the matrix effect.  
The MS was tuned with the analyte solution and the parameters were set based 
on maximum response. Q1 mass of Analyte, Metabolite and IS were found to be 
286.20, 272.10, 290.10 respectively.Q3 mass of them were same as 229.20. 
Dwell Time for analyte, metabolite and IS was 200 msec. At the condtions of 
certain parameters such as CAD GAS of 10.00, CURTAIN GAS 14.00, GAS1 
and GAS 2 as 50 and 55, Ionization Potential and Exit Potential to be 5500 and 
10.00 respectively. For analyte, metabolite and IS: Declustering Potential = 85, 
70 and 85, Collision Energy = 30, 25 and 30 and Exit Potential = 18, 18 and 20 
respectively. 
Serial dilution within the range of 0.1080 – 35.314 ng/mL(ANALYTE) and 
0.1060 – 34.47 ng/mL (METABOLITE)  provided a linear calibration curve fit 
with a weighting factor 1/x2.  
The optimum chromatographic conditions were found to be the use of Hypersil 
Gold C18 (50mmx4.6mm,5µm) column, having Acetonitrile : 10mM 
Ammonium Acetate (90:10) as mobile phase at 0.6 mL/min flow rate. Column 
oven temperature and auto sampler temperature were 40°C and 10°C. Injection 
volume was 10µL and Total run time was 3.5 minutes. The retention times were 
Analyte: 2.20±0.3 min, Metabolite: 2.10±0.3 min, IS : 2.20±0.3 min 
The best extraction procedure of drug from plasma was found to be a        
Liquid- Liquid Extraction by using Extraction Solvent as Tertiary Butyl Methyl 
Ether: n- Hexane (90:10). 
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Under these conditions, the method was proved to be precise, accurate, devoid 
of matrix effect and specific and selective for the analyte. There was no 
carryover of analyte. The mean recovery of Asenapine (80.70%) and N-
Desmethyl Asenapine (80.10%) from spiked plasma samples was consistent and 
reproducible.  
The drug was tested for stability under different conditions and was found to be 
stable. The method was proved to be repeatable during re-injection after long 
periods of time (31.75 hours).  
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5. CONCLUSION 
The main objective of the present work is to develop a new simple, rapid, 
accurate and robust quantitative procedure, to validate, to determine Asenapine 
and N-Desmethyl Asenapine in Human Plasma by High Performance Liquid 
Chromatography-Mass Spectrometry/Mass Spectrometry 
Literature review revealed that only few Analytical methods have been 
reported to determine the Asenapine and its metabolite in plasma samples. An 
attempt was made to develop a LC-MS/MS method for the determination of 
Asenapine and N-Desmethyl Asenapine in human plasma at picogram level 
concentration. 
An efficient bio analytical method for analysis of asenapine and its 
metabolite have been developed using LC-MS/MS. Pre- method validation 
experiments have been performed. Also the developed method was fully 
validated by studying the various parameters like accuracy, precision, 
specificity etc.  
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6. APPENDICES: 
APPENDIX – 1: PREPARATION OF SOLUTIONS: 
 
1. STOCK SOLUTION: 
Analyte: 
2mg of Asenapine Maleate was weighed and transferred into a 2 mL 
volumetric flask. 2 mL of Methanol was added to dissolve and make up 
the volume. The final concentration of 1mg/mL of Asenapine Maleate 
can be calculated as follows: 
Weight of Asenapine Maleate taken in mg  x  Potency( as in basis) x M1 x 1000 
                                            2 mL                                   100                 M2 
Where M1 is molecular weight of Asenapine (free) and M2 is the 
molecular weight of Asenapine Maleate(salt). 
Metabolite: 
2mg of N-Desmethyl Asenapine Maleate was weighed and transferred 
into a 2 mL volumetric flask. 2 mL of Methanol was added to dissolve 
and make up the volume. The final concentration of 1mg/mL of N-
Desmethyl Asenapine Maleate can be calculated as follows: 
Weight of N-Desmethyl Asenapine Maleate x  Potency x M1 x 1000 
                                          2 mL                           100        M2 
Where M1 is molecular weight of N-Desmethyl Asenapine (free) and M2 
is the molecular weight of N-Desmethyl Asenapine Maleate(salt). 
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INTERNAL STANDARD: 
2mg of Asenapine 13C-D3 Maleate was weighed and transferred into a 2 
mL volumetric flask. 2 mL of Methanol was added to dissolve and make 
up the volume to obtain 1µg/mL concentration. The final concentration of 
Asenapine 13C-D3 Maleate can be calculated as follows: 
Weight of Asenapine 13C-D3 Maleate x Potency (as in basis) x M1 x 1000 
                               2 mL                                       100                  M2 
Where M1 is molecular weight of  Asenapine 13C-D3 (free) and M2 is the 
molecular weight of Asenapine 13C-D3 Maleate (salt). 
 
Table- 26 : Preparation of IS stock solution 
Stock Conc 
(µg/mL) 
Stock 
Aliquot(mL) 
Diluent 
Added(mL) 
Final Volume 
(mL) 
Final Conc 
(ng/mL) 
1000 0.250 24.750 25.000 10000.0000 
10 0.025 24.975 25.000 100.000 
 
2. TUNING SOLUTION: 
20µl of each stock solutions were taken and made up to 2ml using 
Methanol. This resulted in 3 solutions of 100ng/ml concentration each, 
which were used as tuning solutions. 
3. BUFFER -1 SOLUTION: (10mm ammonium Formate) 
630.60mg of Ammonium formate was weighed and transferred into 
1000mL volumetric flask containing about 500mL of HPLC water, 
dissolved and 500mL of water was added. It was mixed well and 
sonicated  in Ultrasonic bath for few minutes and Filtered through 0.2µm 
nylon membrane filter. 
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4. BUFFER-2SOLUTION:(10mmPotassium Dihydrogen Orthophosphate) 
1.360gm of Potassium Dihydrogen Orthophosphate was weighed and 
transferred into 1000 mL volumetric flask containing about 500mL of 
HPLC water, dissolved and 500mL of water was added. It was mixed 
well and sonicated in Ultrasonic bath for few minutes and Filtered 
through 0.2µm nylon membrane filter. 
5. MOBILE PHASE: (ACETONITRILE: BUFFFER-1 (90:10, V/V)) 
900 mL of acetonitrile was transferred into 1000mL reagent bottle. 
100mL of Buffer-1 was added. It was mixed well and sonicated in 
Ultrasonic bath for few minutes. Then it was filtered through 0.2µm 
nylon membrane filter. 
6. DILUENT: ACETONITRILE: WATER (50:50%V/V) 
500mL of Acetonitrile was transferred into 1000 mL reagent bottle and 
500mL of HPLC water was added. It was Mixed well and sonicated  in 
Ultrasonic bath for few  minutes. Then it was filtered through 0.2µm 
nylon membrane filter. 
7. WEAK WASH SOLUTION:  METHANOL: WATER (50:50,V/V) 
500mL of Methanol was transferred into 1000ml reagent bottle; 500mL 
of HPLC water was added. This was mixed well using the Sonicator for 
few minutes. Then it was filtered through 0.2µm nylon membrane filter. 
8. STRONG WASH SOLUTION: (METHANOL: WATER (90:10, V/V)) 
900 mL of Methanol was transferred into 1000 mL reagent bottle, and 
100 mL of Water was added .It was mixed well by using Sonicator and 
filtered through 0.2µm nylon membrane filter. 
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APPENDIX- 2 : TERMINOLOGY 
 
Bio Analysis : is a sub-discipline of analytical chemistry covering 
the quantitative measurement of  biological molecules, proteins, DNA, drugs 
and their metabolites in the biological systems 
Bioavailability: Amount of a substance that becomes available to an organism's 
body for bioactivity when introduced through ingestion, inhalation, injection, 
or skin contact 
Bioequivalence: The property wherein two drugs with identical active 
ingredients or two different dosage forms of the same drug possess similar 
bioavailability and produce the same effect at the site of physiological activity 
Method Development: Refers to the process of formulating the materials, 
conditions, and protocol for measuring an analyte. Method development is 
mainly carried out by industry. 
Method Validation: The process of testing a measurement procedure to assess 
its performance and to validate that performance is acceptable.  
Tuning: Tuning is the adjustment of working parameters of LC-MS/MS to 
enable an operator to get the best signal possible for the analyte by optimizing 
the Q1 mass, Q3 mass of analyte, metabolite and Internal Standard based on 
molecular weights 
Elution: The process of extracting a substance adsorbed to another by means of 
a suitable solvent or buffering agent as in column chromatography. 
Mobile Phase: The mobile phase is the part of the chromatographic system 
which carries the solutes through the stationary phase. The mobile phases are 
either liquids or gases. The liquid mobile phases are used to adjust the 
chromatographic separation and retention in liquid chromatography and the  
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temperature of the gas mobile phase is used to adjust the retention in gas 
chromatography. 
CC: a calibration curve is a general method for determining the concentration 
of a substance in an unknown sample by comparing the unknown to a set of 
standard samples of known concentration. 
QC: Quality control is a generic term that refers to the monitoring and 
assessment of laboratory testing processes to identify problems and maintain 
performance. 
Linearity: The linearity of an analytical method is its ability to elicit test results 
that are directly proportional to the concentration of analytes in samples within 
a given range or proportional by means of well-defined mathematical 
transformations 
Specificity: The ability of an analytical method to measure only the sought-for 
analyte or measurand. Numerically characterized by determination of 
interferences and non-specific responses to other analytes or materials. 
Selectivity: Selectivity refers to the extent to which a method can determine 
particular analyte in mixtures or matrices without interferences 
from other components. 
Matrix Effect: The combined effect of all components of the sample other than 
the analyte on the measurement of the quantity. If a specific component can be 
identified as causing an effect then this is referred to as interference. 
ASCOT: All Samples Carry over Test is used to check if the response of a high 
concentration sample is carried to the next injection by injecting a blank sample 
after a high concentration sample. 
Precision: Closeness of agreement between quantity values obtained by 
replicate measurements of a quantity, under specified conditions.  
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Accuracy: Closeness of the agreement between the result of a measurement and 
a true value of the measured 
Recovery: The measurable increase in analyte concentration or activity in a 
sample after adding a known amount of that analyte to the sample. 
Characterizes the ability of an analytical method to correctly measure pure 
analyte when added to the matrix routinely analyzed. 
Stability: The term system stability has been defined as the stability of the 
samples being analyzed in a sample solution.  
System Suitability: System suitability is defined by ICH as "the checking of a 
system, before or during analysis of unknowns, to ensure system performance. 
Haemolysed Plasma: the plasma with ruptured erythrocytes (red blood cells) 
and the release of their contents (cytoplasm) into surrounding fluid (e.g., blood 
plasma). 
Internal Standard: An internal standard is a known amount of a compound, 
different from analyte that is added to the unknown. Signal from analyte is 
compared with signal from the internal standard to find out how much analyte is 
present. 
Coefficient Of Variation: The relative standard deviation, i.e., the standard 
deviation expressed as a percentage of the mean [CV=100(s/x)]. 
Standard Deviation: A statistic that describes the dispersion or spread of a set 
of measurements about the mean value of a gaussian or normal distribution. 
Regression Model: The equation for the line obtained in linear regression 
calculations (Y = a + bX). This equation is used to calculate the amount of 
systematic error from the comparison of methods experiment. 
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